Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857 ·Status: RECRUITING

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

NCT06735391 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

NCT04695925 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821 ·Status: RECRUITING ·Phase: PHASE2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

NCT06380348 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

NCT05011487 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

NCT05009836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936 ·Status: SUSPENDED

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

NCT03414814 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970 ·Status: COMPLETED

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

NCT04974879 ·Status: UNKNOWN ·Phase: PHASE2

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

NCT04391283 ·Status: UNKNOWN

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326 ·Status: COMPLETED

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

NCT05104281 ·Status: UNKNOWN ·Phase: PHASE3

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

NCT05020769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2